Why is Helus Pharma stock tumbling today?
Helus Pharma (HELP) shares fell 25.4% in pre-market trading after reporting Phase 3 trial success for HLP003, a treatment for major depressive disorder, but missing Q2 earnings estimates by $0.68 per share. The stock declined despite meeting primary endpoints, with investors reacting to the earnings miss and broader market downturn.
How this was made
The 30-second read
Why it matters
The combination of a GAAP loss and mixed Phase 3 results created a sharp selloff, outweighing the positive efficacy signal.
Market read
The news directly impacts HELP's share price and may influence sentiment toward similar biotech companies releasing trial data.
What to watch
Potential future revenue from HLP003 if regulatory approval follows; market may have over‑reacted to adverse safety signals.
Background
Helus Pharma (HELP) is a clinical‑stage biotech developing a deuterated psilocin for major depressive disorder.
Ticker impact
Helus Pharma reported a Q2 loss of $1.41 per share and released Phase 3 trial data, causing a 25.4% pre‑open selloff.
downward pressure as investors discount earnings miss and safety concerns from the trial.
Both the earnings miss and the trial data were disclosed today, providing fresh, material information that moved the stock sharply.
Market effects
Highlights risk for biotech stocks releasing trial data alongside earnings.
Contributes to broader Nasdaq weakness in a risk‑off environment.
Limited to U.S. biotech sector; no immediate global macro effect.
Counterpoint
Positive trial endpoints could support a rebound if investors focus on efficacy data over earnings miss.
Key entities
- companyHelus Pharma
Biotech firm reporting earnings and trial data.




